Immune-mediated regression of established B16F10 melanoma by intratumoral injection of attenuated Toxoplasma gondii protects against rechallenge.
about
Spontaneous regression of tumour and the role of microbial infection--possibilities for cancer treatmentThe Tumor Macroenvironment: Cancer-Promoting Networks Beyond Tumor BedsIntratumoral interferon-gamma increases chemokine production but fails to increase T cell infiltration of human melanoma metastases.Nonreplicating, cyst-defective type II Toxoplasma gondii vaccine strains stimulate protective immunity against acute and chronic infectionAMA1-deficient Toxoplasma gondii parasites transiently colonize mice and trigger an innate immune response that leads to long-lasting protective immunity.Regulatory B cells preferentially accumulate in tumor-draining lymph nodes and promote tumor growthAttenuated Toxoplasma gondii Stimulates Immunity to Pancreatic Cancer by Manipulation of Myeloid Cell Populations.The Cytolytic Amphipathic β(2,2)-Amino Acid LTX-401 Induces DAMP Release in Melanoma Cells and Causes Complete Regression of B16 MelanomaThe Diverse Role of NK Cells in Immunity to Toxoplasma gondii InfectionIn situ vaccination with cowpea mosaic virus nanoparticles suppresses metastatic cancer.Attenuated Toxoplasma gondii therapy of disseminated pancreatic cancer generates long-lasting immunity to pancreatic cancerAvirulent Toxoplasma gondii generates therapeutic antitumor immunity by reversing immunosuppression in the ovarian cancer microenvironment.Secretion of Rhoptry and Dense Granule Effector Proteins by Nonreplicating Toxoplasma gondii Uracil Auxotrophs Controls the Development of Antitumor Immunity.Targeting tumors with nonreplicating Toxoplasma gondii uracil auxotroph vaccines.Potential therapeutic anti-tumor effect of a Salmonella-based vaccine.Intratumoral immunotherapy for melanoma.Combination of Plant Virus Nanoparticle-Based in Situ Vaccination with Chemotherapy Potentiates Antitumor Response.MHC I presentation of Toxoplasma gondii immunodominant antigen does not require Sec22b and is regulated by antigen orientation at the vacuole membrane.Trypanosoma cruzi extracts elicit protective immune response against chemically induced colon and mammary cancers.Toxoplasma Modulates Signature Pathways of Human Epilepsy, Neurodegeneration & Cancer.Melanoma Induces, and Adenosine Suppresses, CXCR3-Cognate Chemokine Production and T-cell Infiltration of Lungs Bearing Metastatic-like Disease.Cancer therapy in a microbial bottle: Uncorking the novel biology of the protozoan Toxoplasma gondii.Necrosis and apoptosis in Trichinella spiralis-mediated tumour reductionUse and safety of intratumoral application of European mistletoe (Viscum album L) preparations in Oncology.Non-replicating Toxoplasma gondii reverses tumor-associated immunosuppressionHypo-fractionated Radiation, Magnetic Nanoparticle Hyperthermia and a Viral Immunotherapy Treatment of Spontaneous Canine Cancer.Harnessing innate lung anti-cancer effector functions with a novel bacterial-derived immunotherapy.Antitumor activity of human hydatid cyst fluid in a murine model of colon cancer.Parasites as negative regulators of cancer
P2860
Q26774238-3860D18E-F0BE-4185-97C9-6A2197F293D4Q26799120-9B26E52B-6D30-48DE-9861-999A105E8048Q30276128-DEB056F6-E00E-406D-A594-B2FB0E90FF20Q35439431-CE31B0A1-EF0B-4A1D-A0AA-D8628D9F32D7Q35609307-16AB8B14-0E78-41DF-A1A4-BF211154F03DQ35866355-34424AFB-7A14-4DF1-BB30-B34CA895852DQ35920573-CA6199EB-3241-42AF-9079-7061215694B8Q35924903-A8EAC107-4A80-4A17-830A-AFFA0F67F57FQ35935856-7F5BBA8B-C568-441C-89B0-9F0E744DAA72Q36649674-D120F84E-2108-410F-AB01-ED9DD1FA381FQ36821108-98F66134-7B7E-45A3-A616-45E6627C950EQ36986107-75FD49BB-84E5-4C6C-8F80-A71572F6BA2AQ37119146-E5AC4168-EF8C-429A-A5D0-FC0160861383Q37184436-A7582257-EAAB-4BB5-8913-08E706B97821Q37530067-48E37FE2-5A0C-42AE-8821-309359ADDE7AQ38518518-8865A479-17B9-4C3C-B084-7C737C6C7C64Q38708960-05EDD787-B955-42B7-B983-5F630EC23C36Q38784040-16EC3F87-BBEA-4D9B-9DA8-25ED080FABC8Q38823310-7D4B84A5-F808-4C43-A585-BDD3A45E0303Q40047888-3EAACFCA-370B-4C1E-9664-C9C46CB58D42Q40864107-04847C72-5C04-40ED-9925-82F018D11C9EQ41068755-3F9BC56B-A5C6-4E3B-AE60-22626DA8C24DQ41118116-1A854CCC-6690-4146-B98C-DBD96DBD6939Q41634773-F96BCB7D-898A-480E-BF5C-FC5BE9997836Q42795928-BF83BE3C-9A0E-47F7-9F42-12848D8677E1Q47331772-09A718BB-8CB5-4D59-B323-AFDB2980DB3BQ50535273-D2579B29-4464-4138-A6F8-8E906B6ED018Q51785776-42FB96D0-A3DA-472B-862E-0459D80C0340Q57801266-F550710A-1887-4902-8909-16D065A59458
P2860
Immune-mediated regression of established B16F10 melanoma by intratumoral injection of attenuated Toxoplasma gondii protects against rechallenge.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Immune-mediated regression of ...... protects against rechallenge.
@ast
Immune-mediated regression of ...... protects against rechallenge.
@en
type
label
Immune-mediated regression of ...... protects against rechallenge.
@ast
Immune-mediated regression of ...... protects against rechallenge.
@en
prefLabel
Immune-mediated regression of ...... protects against rechallenge.
@ast
Immune-mediated regression of ...... protects against rechallenge.
@en
P2093
P2860
P356
P1476
Immune-mediated regression of ...... protects against rechallenge.
@en
P2093
Barbara A Fox
David J Bzik
David W Mullins
Jason R Baird
Katelyn T Byrne
Marcus Bosenberg
Mary Jo Turk
Matthew P Alexander
Mee Rie Sheen
Patrick H Lizotte
P2860
P304
P356
10.4049/JIMMUNOL.1201209
P407
P577
2012-12-07T00:00:00Z